China Conquers Ac-225 Core Technology! Tsinghua and PanMediso Solve Global Cancer Isotope Dilemma
-- A milestone breakthrough has been achieved in China's nuclear medicine field! Tsinghua University and PanMediso announced today that their joint industry-university-research project has successfully overcome the core technology for the preparation of the new isotope Ac-225 (Actinium-225). This marks China's achievement of self-sufficiency and control in the globally scarce α-emitting isotope sector, breaking foreign monopolies and providing a "Chinese solution" for global cancer treatment.
Isotope Ac-225: The Conflict of Soaring Demand and Supply Shortages
Ac-225, renowned as the new generation "star isotope" for its precise targeted therapy capabilities, releases α-particles with a linear energy transfer (LET) nearly a hundred times higher than that of β-emitting isotopes. Its tumor-killing effect is significantly superior to β-isotopes, and α-isotopes can directly damage the DNA double strands of tumor cells, leading to permanent cell destruction. Currently, there are over 70 development pipelines for Ac-225 radiopharmaceuticals targeting high-incidence cancers such as prostate cancer, neuroendocrine tumors, and lung cancer, but the annual supply is less than 2 curies (Ci) — only sufficient to meet the needs of about 2,000 patients, severely restricting clinical translation.
From "Bottleneck" to "Made in China": Breaking the Preparation Technology Ice
Faced with the global challenges of Ac-225 preparation, Tsinghua University and the PanMediso team innovatively developed "accelerator-driven" preparation technology, overcoming three core bottlenecks:
- Efficient nuclear reaction pathway optimization: Enhancing Ac-225 yield.
- Efficient separation and purification processes: Achieving a purity of 99.95%, meeting pharmaceutical standards.
- Automated irradiation-extraction systems: Ensuring stable and controllable production.
This technology makes China one of the few countries globally capable of independent full-chain production of Ac-225, with an expected annual production capacity in the curie range, supporting over 50 clinical research projects.
Building a "Nuclear Health Protection" Ecosystem: Advancing Clinical Translation and Universal Healthcare
To accelerate technology implementation, PanMediso is simultaneously promoting industrial ecosystem construction. A clinical research alliance has been initiated, signing agreements with The Hong Kong Polytechnic University and HKSH Medical Group to conduct clinical trials surrounding Ac-225 radiopharmaceuticals.
The Raymednov health service platform has also launched, aggregating top industry experts to provide nuclear medicine education, public health consultations, and interpretations of international cutting-edge technologies. The platform aims to eliminate public misconceptions about nuclear medicine, ensuring cancer-fighting technologies benefit the populace.
A Comprehensive Innovation System: China's Global Role in Nuclear Pharmaceuticals
Tsinghua University and PanMediso, in collaboration with The Hong Kong Polytechnic University and HKSH Medical Group, are jointly creating a "four-in-one" nuclear pharmaceutical ecosystem. This system covers the entire process from isotope preparation and radiopharmaceutical development to clinical services, driving the Chinese nuclear pharmaceutical industry from technological catch-up to global leadership.
"Ac-225 preparation is not just a technological breakthrough but a solemn commitment to life and health," said the technical head of PanMediso. "We will continue to deepen the integration of industry, academia, and research, allowing more 'Made in China' radiopharmaceuticals to illuminate the path to cancer treatment."
About PanMediso
PanMediso is one of the few leading enterprises in nuclear medicine technology platforms with a global intellectual property layout, focusing on the preparation of medical isotopes, radiopharmaceutical development, and precision diagnosis and treatment solutions, committed to enhancing human health through innovative technology.
Contact Info:
Name: Miss Li
Email: Send Email
Organization: PanMediso
Website: http://www.panmedisoholdings.com
Release ID: 89167703
In the event of any inaccuracies, problems, or queries arising from the content shared in this press release, we encourage you to notify us immediately at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our diligent team will be readily available to respond and take swift action within 8 hours to rectify any identified issues or assist with removal requests. Ensuring the provision of high-quality and precise information is paramount to us.
